FLT4 anticorps

N° du produit ABIN2665455

Cet anticorps anti-FLT4 est un anticorps Souris Monoclonal détectant FLT4 dans FACS. Adapté pour Humain.

Aperçu rapide pour FLT4 anticorps (ABIN2665455)

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FLT4 est non-conjugé

Application: Flow Cytometry (FACS)

Clone: 9D9F9

Détail du produit anti-FLT4 anticorps

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur FLT4

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Autre désignation: VEGFR-3

Sujet: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling